Related Experiment Videos
Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist
1Department of Pharmacology, Creighton University School of Medicine, Omaha, Nebraska 68178.
Abstract:
The effects of the adenosine A1 agonist N6-cyclohexyladenosine (CHA) on MPTP-induced dopamine (DA) depletion in the striatum of C57BL/6 mice were studied. Twenty hours after a single injection of MPTP (30 mg/kg, s.c.), the toxin caused 62% depletion of striatal DA. CHA (0.2-3 mg/kg, s.c.), when given together with MPTP, prevented the toxin-induced DA depletion in a dose-dependent manner. This protective action was apparently mediated by the A1 receptors, because this effect was selectively antagonized by pretreating the animals with the A1 antagonist 8-cyclopentyl-1,3-dipropylxanthine (25 mg/kg, i.p.) but not with the A2 antagonist 1,3-dipropyl-7-methylxanthine (25 mg/kg, i.p.). When CHA (3 mg/kg) was injected 5 h after MPTP administration, at which point striatal DA levels were already reduced significantly, a rapid and complete recovery of the striatal DA levels occurred. These neurochemical data suggest that the A1 agonist CHA is potentially useful as a neuroprotective agent against MPTP-induced toxicity.
Insights
The adenosine A1 agonist N6-cyclohexyladenosine (CHA) protects against MPTP-induced dopamine depletion in mice. CHA demonstrated neuroprotective effects against MPTP toxicity, suggesting therapeutic potential.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin that causes dopamine depletion in the striatum, modeling Parkinson's disease.
- Adenosine A1 receptors play a role in regulating neurotransmitter release and neuronal function.
Purpose of the Study:
- To investigate the neuroprotective effects of the adenosine A1 agonist N6-cyclohexyladenosine (CHA) against MPTP-induced dopamine depletion in mice.
Main Methods:
- C57BL/6 mice were administered MPTP (30 mg/kg) to induce dopamine depletion.
- Varying doses of CHA (0.2-3 mg/kg) were administered concurrently with MPTP.
- The effect of CHA was assessed by measuring striatal dopamine levels.
- Receptor specificity was confirmed using A1 and A2 antagonists (8-cyclopentyl-1,3-dipropylxanthine and 1,3-dipropyl-7-methylxanthine, respectively).
Main Results:
- MPTP administration led to a 62% depletion of striatal dopamine.
- Concurrent administration of CHA dose-dependently prevented MPTP-induced dopamine depletion.
- The protective effect of CHA was selectively blocked by the A1 antagonist but not the A2 antagonist.
- Administering CHA 5 hours after MPTP resulted in a rapid and complete recovery of striatal dopamine levels.
Conclusions:
- The adenosine A1 agonist CHA exhibits significant neuroprotective properties against MPTP-induced dopamine depletion.
- These findings suggest that CHA may be a potential therapeutic agent for conditions involving dopaminergic neurotoxicity.